TGFB1 and systemic lupus erythematosus: To treat SLE and other autoimmune diseases with low IL-2 production, one could induce and expand autologous SLE CD4 Tregs ex vivo with IL-2 and TGF-β for subsequent adoptive transfer of these cells back to the donor (11).